Table 2.
Various clinical parameters in low and high groups when miR-150 was estimated initially
| Parameters | Mir-150 initial ≤ 1 N = 35 | Mir-150 initial > 1 N = 15 | P value | |
|---|---|---|---|---|
| Age (years) | Mean ± S.D | 33.9 ± 10.5 | 38.85 ± 10.27 | 0.262 |
| Sex n (%) | Male | 10 (45.5) | 5 (62.5) | 0.409 |
| Female | 13 (54.5) | 3 (37.5) | ||
| TLC initial x109/L | Median | 9.5 | 36 | 0.023* |
| Range | 0.7- 42.3 | 1.68-112.58 | ||
| Plts initial x109/L | Median | 40 | 33 | 0.649 |
| Range | (2.0-211) | (2.0-290) | ||
| HB initial gm/dl | Median | 7.9 | 7.3 | 0.094 |
| Range | 5.6-12.1 | 4.8-11.5 | ||
| PB initial Blasts% | (mean ± S.D) | 40.06 ± 27.85 | 58.2 ± 25.87 | 0.036* |
| BM initial cellularity n(%) | Normocellular | 9 (25.7) | 3 (20.0) | 0.362 |
| Hypocellular | 3 (8.6) | 2 (13.3) | ||
| Hypercellular | 14 (40) | 9 (60.0) | ||
| Extrahypercellular | 9 (25.7) | 1 (6.7) | ||
| BM initial blast% | (mean ± S.D.) | 62.6 ± 20.07 | 67.93 ± 20.0 | 0.393 |
| FAB classification n(%) | M0 | 1 (2.9) | 0 | 0.185 |
| M1 | 7 (20) | 1 (6.7) | ||
| M2 | 13 (37.1) | 5 (33.3) | ||
| M3 | 1 (2.9) | 4 (26.7) | ||
| M4 | 8 (22.9) | 2 (13.3) | ||
| M5 | 2 (5.7) | 0 | ||
| M7 | 2 (5.7) | 2 (13.3) | ||
| Others (phenotypic) | 1 (2.9) | 1 (6.7) | ||
| IPT n(%) | Myeloid | 20(57.1) | 9 (60) | 0.353 |
| Mono | 1(2.9) | 0 | ||
| Myeloma | 6(17.1) | 0 | ||
| Myeloid with aberrant | 5(14.3) | 2 (13.3) | ||
| Myeloid-B | 1(2.9) | 1 (6.7) | ||
| Others | 2(5.7) | 3 (20) | ||
| FLT3 n(%) | Wild | 26(74.3) | 8 (53.3) | 0.346 |
| Mutant | 5(14.3) | 4 (26.7) | ||
| NA | 4(11.8) | 3 (20) | ||
| Cytogenetics n(%) | T (9, 22) | 1(4.8) | 0 | 0.138 |
| T (8, 21) | 2(9.5) | 0 | ||
| T (15, 17) | 1(4.8) | 3 (27.3) | ||
| Normal karyotype | 7(33.3) | 6 (54.2) | ||
| Others | 10(47.6) | 2 (18.2) | ||
| BM Cellularity N(%) D28 | Normocellular | 13(52) | 6 (50) | 0.067 |
| Hypocellular | 9(36) | 2 (16.7) | ||
| Hypercellular | 1(4) | 4 (33.3) | ||
| NA | 2(8) | 0 | ||
| Blast n(%) D28 | Less than or equal 5 | 18(75.0) | 9 (75) | 0.05 |
| More than 5 | 6(25) | 3 (25) | ||
| TLC x109/L D28 | Median | 2.0 | 4.27 | 0.023* |
| Range | (0.1-16.3) | (0.56-16) | ||
| HB gm/dl D28 | Median | 7.7 | 8.7 | 0.013* |
| Range | (3.3-10.3) | (7-10) | ||
| Plts x109/L D28 | Median | 84.5 | 333 | 0.014* |
| Range | (2.00-579) | (5-558) | ||
| PB blasts n(%) D28 | Equal zero | 16(76.2) | 7 (87.5) | 0.50 |
| More than 1 | 5(23.8) | 1 (12.5) | ||
| Response to treatment n(%) | CR | 10(62.5) | 22 (64.7) | 0.98 |
| Refractory | 3(18.8) | 6 (17.6) | ||
| NA | 3(18.8) | 6 (17.6) | ||
| Relapse | Relapse | 2(16.7) | 5 (19.2) | 0.79 |
| No relapse | 9(75) | 17 (65.4) | ||
| NA | 1(8.3) | 4 (15.4) | ||
| Early death | Before D28 | 3(50) | 7 (53.8) | 0.87 |
| After D28 | 3(50) | 6 (46.2) | ||
TLC: total leucocytic count, HB: haemoglobin, PLT: platelet count, PB: peripheral blood, BM: bone marrow, FAB: French American British classification, IPT: immunophenotyping, D28: day 28 of treatment, NA: non-available, CR: complete remission, OS: overall survival.